Thanks to the witnesses for their presentations today and for all their work, particularly over the past two years. I remember there was considerable criticism, particularly in this committee, of the fact that Canada was unable to produce Canadian vaccines in response to the pandemic and that it didn't have a strategy.
Mr. Costen, if memory serves me, you confirmed that earlier when you said that we didn't know what to do in October 2020 after staking everything on the Chinese vaccine CanSino.
We had a first phase of $900 million and a second of $1.3 billion, for a total of $2.2 billion, $1.6 billion of which has been spent. If I'm not mistaken, that leaves us with $600 million to spend.
Thus far, how has that government spending tangibly increased Canada's biomanufacturing capacity in the short and medium terms? What will we do with the remaining $600 million?